Why the study?
Do antihypertensive drugs (ARBs, CCBs) improve central aortic pressure and biomarkers of vascular function?
Do antihypertensive drugs (ARBs, CCBs) improve central aortic pressure and biomarkers of vascular function?
Antihypertensive therapies, particularly ARBs and CCBs, may offer long-term vascular benefits beyond blood pressure control, as evidenced by improvements in biomarkers like hsCRP, adiponectin, and HOMA-IR.
Answers are grounded in this paper and cite their sources.
Biomarker gains with antihypertensives remain hypothesis-generating; prospective outcome trials needed before any practice shift.
Biomarkers are being increasingly used in the study of cardiovascular disease because they provide readily quantifiable surrogate endpoints and allow accurate assessment of the effects of therapy on particular pathological processes. However, in order to be useful, biomarkers must be relevant, predictable, accurate, and reproducible. There is compelling evidence from large-scale clinical trials that inhibitors of the renin-angiotensin system [angiotensin-converting enzyme inhibitors and angiotensin type II receptor blockers (ARBs)] and calcium channel blockers (CCBs) may have beneficial effects beyond blood pressure control in the treatment of hypertension. Biomarkers are expected to provide further insight into these beneficial effects and allow for quantitative assessment. This review summarizes the published clinical evidence on the effects of various antihypertensive drugs, particularly ARBs (e.g. losartan and olmesartan medoxomil) and CCBs (e.g. amlodipine), alone and in combination with other agents (e.g. hydrochlorothiazide), on central aortic pressure and the biomarkers high-sensitivity C-reactive protein (hsCRP), adiponectin, cystatin C, homeostasis model assessment of insulin resistance (HOMA-IR), procollagen, tumor necrosis factor-α, and interleukin-6. Of these biomarkers, the benefits of antihypertensive therapy on hsCRP, adiponectin, and HOMA-IR reflect a potential for quantifiable long-term vascular benefits.
No takes yet. Share an insight, caveat, or question.
Bobby V. Khan (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: